Skip to search.
 TSX Up1.00% TSX Ventures 0.00%

More On SSS.V

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Stem Cell Therapeutics Corp. (SSS.V)

-TSXV
0.35 Up 0.02(4.55%) 3:58PM EDT
Add to Portfolio
ProfileGet Profile for:
Stem Cell Therapeutics Corp.
96 Skyway Avenue
Toronto, ON M9W 4Y9
Canada - Map
Phone: 416-595-0627
Website: http://www.stemcellthera.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:14

Business Summary 

Stem Cell Therapeutics Corp., a biopharmaceutical development company, develops and commercializes stem cell-based therapies for cell therapy and regenerative medicine. Its products include Tigecycline, which is in phase I for study in patients with relapsed or refractory acute myeloid leukemia (AML); SIRPaFc, an antagonist of the CD47- SIRPa interaction to alleviate CD47-mediated suppression and promote anti-tumour responses, which is in pre-clinical stage; CD200-specific monoclonal antibody, a human monoclonal antibody that blocks the activity of CD200 and is clinical development stage; and TTI-1612, a non-oncology asset that recently completed dosing in a 28-patient Phase I trial in interstitial cystitis patients. The company was formerly known as Neurogenesis Biotech Corp. and changed its name to Stem Cell Therapeutics Corp. in October 2004. Stem Cell Therapeutics Corp. was incorporated in 2004 and is headquartered in Toronto, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Stem Cell Therapeutics Corp.

Key Executives 
 PayExercised
Dr. Bjorn Johan Niclas Stiernholm Ph.D.,
Chief Exec. Officer, Pres and Director
20.00k0.00
Mr. James Parsons CA,
Chief Financial Officer
93.00k0.00
Dr. Robert Uger Ph.D.,
Chief Scientific Officer
N/AN/A
Dr. Beverly Incledon Ph.D., 46
VP of Devel.
N/AN/A
Dr. Michael G. Hill Ph.D.,
Head of Calgary Site and Member of the Clinical Advisory Board
N/AN/A
Amounts are as of 2012-12-31 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.